Physician profile
Robert Tamayev
NPI 1659786440
$321,295.32
in general payments reported to CMS, 2019-2025
36 companies · $111K in 2025
The $111K reported for 2025 was more than what 98% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,908 · 2020: $5,810 · 2021: $21K · 2022: $11K · 2023: $76K · 2024: $96K · 2025: $111K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $217K · Consulting Fee: $30K · Food and Beverage: $28K · Travel and Lodging: $6,665 · Education: $356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $217,056.73 |
| Consulting Fee | $29,865.50 |
| Food and Beverage | $28,098.81 |
| Travel and Lodging | $6,665.23 |
| Education | $355.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $150,021.37 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $80,824.86 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $40,493.04 | 2019-2025 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $11,013.07 | 2020-2022 | |
| Pharming Healthcare, INC. | $7,545.35 | 2020-2025 | Ruconest |
| Genentech USA, INC. | $5,943.13 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $4,529.95 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $3,827.78 | 2022-2025 | Orladeyo |
| Sanofi-Aventis U.S. LLC | $3,366.42 | 2022-2025 | |
| Regeneron Pharmaceuticals, INC. | $2,791.32 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $2,691.47 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Optinose US, INC. | $1,880.79 | 2020-2025 | |
| Pfizer INC. | $1,347.57 | 2019-2025 | |
| Amgen INC. | $1,051.50 | 2021-2025 | Tezspire, Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $754.47 | 2021-2025 | Takhzyro, Cuvitru, Eohilia |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $417.01 | 2019-2023 | Grastek, Odactra, Ragwitek |
| Leo Pharma INC. | $405.24 | 2022-2025 | Adbry, Anzupgo |
| Kaleo, INC. | $330.21 | 2020-2024 | Auvi-Q |
| Incyte Corporation | $278.70 | 2023-2025 | Opzelura |
| Abbvie INC. | $255.70 | 2022-2025 | Rinvoq |
| Galderma Laboratories, L.P. | $234.35 | 2024-2025 | Nemluvio |
| Verona Pharma, INC. | $185.02 | 2025 | Ohtuvayre |
| Csl Behring | $171.09 | 2025 | Andembry, Haegarda |
| Ars Pharmaceuticals Operations, INC. | $147.77 | 2025 | Neffy |
| Tersera Therapeutics LLC | $134.82 | 2022-2025 | Quzyttir |
| Lilly USA, LLC | $124.75 | 2024-2025 | Ebglyss, Taltz |
| Grifols USA, LLC | $91.26 | 2020-2025 | Xembify |
| Arcutis Biotherapeutics, INC. | $85.54 | 2025 | Zoryve |
| Hikma Pharmaceuticals USA | $85.08 | 2023 | Ryaltris |
| Dermavant Sciences, INC. | $72.00 | 2023-2024 | Vtama |
| Genentech, INC. | $47.95 | 2020 | |
| Eyevance Pharmaceuticals LLC | $39.78 | 2020 | |
| Horizon Therapeutics Plc | $35.80 | 2021 | |
| Ionis Pharmaceuticals, INC. | $32.57 | 2025 | Dawnzera |
| Merck Sharp & Dohme LLC | $23.50 | 2023 | |
| Aimmune Therapeutics, INC. | $15.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Tamayev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.